Five years after the U.S. Preventive Services Task Force recommended against prostate-specific antigen-based screening for all men, rates of advanced prostate cancer continued to increase in men 50 and over in the U.S., according to a new study.
Text messages were not effective in reminding breast cancer patients to maintain their aromatase inhibitor regimens, a study conducted by SWOG shows.
Researchers at the University of California, Los Angeles found that a first-line combination of atezolizumab, an immunotherapy drug that boosts the body's natural defenses, and bevacizumab, an anti-angiogenesis drug that inhibits the growth of tumors' blood vessels, significantly improves survival for people with hepatocellular carcinoma, the most common type of liver cancer.
Cancer patients with no health insurance or those enrolled in Medicaid see smaller survival benefits from experimental therapies in clinical trials, according to a study published April 30 in JAMA Network Open.
Libtayo (cemiplimab) demonstrated clinically meaningful and durable responses in patients with advanced basal cell carcinoma who had progressed on or were intolerant to prior hedgehog pathway inhibitor therapy.
A holistic tumor sampling method that more accurately detects genetic alterations in tumors has been developed by researchers from the Crick, Roche and The Royal Marsden NHS Foundation Trust. The study was published in Cell Reports.
The primary endpoint of overall survival was met in a phase III trial comparing the PD-1 inhibitor Libtayo (cemiplimab) to platinum-doublet chemotherapy in patients with first-line locally advanced or metastatic non-small cell lung cancer who tested positive for PD-L1 in ≥50% of tumor cells.
The phase III PROfound trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments (e.g. enzalutamide and abiraterone) has demonstrated improvement in overall survival.
GARNET study demonstrates potential of dostarlimab to treat recurrent or advanced endometrial cancer
The GARNET trial demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient endometrial cancer who progressed on or after a platinum-based regimen.
Researchers at the MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1).